Month: August 2020

SCOTTSDALE, Ariz., Aug. 10, 2020 (GLOBE NEWSWIRE) — AgJunction Inc. (TSX: AJX) announces the launch of our updated website at www.agjunction.com.Our primary goal during the update process was to create a modern, and more valuable site across all platforms and devices. Specifically, we wanted to focus on making it easier for our users to locate valuable information about us and our technical solutions.We have reorganized information into categories including OEM and Farmer solutions as well as Modular Hardware and Software offerings and capabilities that solve the most complex challenges related to off-road automation.  Sharon Woods, Sr. Director of Marketing and Program Management at AgJunction stated “We are excited about the site and its continuous expansion to help our viewers.” If you are a farmer trying to increase productivity...

Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Open-Label Extension StudyInitiated Phase 1/2 Clinical Trial of ACN00177 for the Treatment of HomocystinuriaAUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today reported its second quarter 2020 financial results, and provided recent corporate and program highlights.“Despite the operating challenges posed by the global pandemic, we continued to advance our pegzilarginase program in the first half of the year. The presentation of long-term data showing sustained lowering of arginine levels and durable clinical...

Early Interim Data from Registrational Phase 2 TRIDENT-1 Study of Lead Drug Candidate Repotrectinib Anticipated in Third QuarterFour Clinical Studies of Three Drug Candidates Ongoing; Early Interim TPX-0022 Data Anticipated in Fourth Quarter Cash, Cash Equivalents, and Marketable Securities of $710 Million Expected to Fund Current Operations into 2023SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results and operational updates for the second quarter ended June 30.“We achieved many important milestones since our first quarter update in May, including advancing our pipeline of four drug candidates, sharing our preclinical combination data for repotrectinib...

AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) — Ideal Power Inc. (NASDAQ: IPWR) (the “Company”), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bi-directional power switches, was awarded a $1.2 million contract by Diversified Technologies, Inc. (DTI) to supply B-TRAN™ devices as part of a two-year, $3.0 million contract awarded to DTI by the United States Naval Sea Systems Command (NAVSEA). The objective of the project is to develop and demonstrate B-TRAN™ enabled high efficiency 12kV medium voltage direct current (MVDC) circuit breakers for the U.S. Navy as part of their ship electrification program. The project is funded under the Department of Defense’s Rapid Innovation Fund, which is designed to accelerate the commercialization of high-value, high-impact technologies.Ideal Power’s...

WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of Radio-Immuno-Therapeutics (RITs) to treat patients with severe COVID-19, today announced a partnership with IsoTherapeutics Group, LLC (Angleton, TX), to develop and manufacture a RIT for the potential treatment of severe COVID-19.IsoTherapeutics will modify Monopar’s proprietary urokinase plasminogen activator receptor (uPAR) targeted antibody, MNPR-101, by making conjugates that will allow the attachment of therapeutic radioisotopes supplied by NorthStar, creating a platform of uPAR-targeted RIT (uPRIT) candidates to be evaluated as treatments for severe COVID-19.  The plan is for IsoTherapeutics...

CHICAGO, Aug. 10, 2020 (GLOBE NEWSWIRE) — International Association of Women (“IAW”) today announced the launch of extended virtual programs. IAW is the subsidiary of Professional Diversity Network, Inc. (NASDAQ: IPDN), (“PDN” or the “Company”), a global developer and operator of online and in-person networks that provide access to networking, training, educational and employment opportunities for diverse individuals.Earlier this year, IAW launched two new initiatives to provide support and resources to help connect women: Regional Networking Events and Virtual Networking Roundtables. According to a recent survey conducted by Professional Convention Management Association (“PCMA”), a widely recognized network of business events strategists, 87% of event industry professionals said they have canceled — and 66% have postponed — events...

In July, SCYNEXIS announced that it had successfully conducted pre-NDA meetings with the FDA regarding ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC) more commonly known as vaginal yeast infection. NDA submission for this indication remains on track for Q4 2020.In July, SCYNEXIS held an investor event with two key opinion leaders (KOLs) to discuss patient perspectives, unmet needs and treatment options in VVC, as well as the related commercial opportunity. This event followed the successful completion of the Phase 3 VANISH program evaluating oral ibrexafungerp for the treatment of VVC.Enrollment is ongoing in the Phase 3 CANDLE study of oral ibrexafungerp for the prevention of recurrent vaginal yeast infections; top-line results and supplemental NDA submission anticipated in the second half of 2021. JERSEY CITY, N.J.,...

TYMLOS® U.S. net sales of $50 million, with 22% year over year growthCompletion of enrollment in ATOM Phase 3 expected this weekPhase 3 Trials: wearABLe and EMERALD remain on trackConference call scheduled for 8:30 a.m. ET todayWALTHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the second quarter ended June 30, 2020 and provided a business update.“Completing the elacestrant transaction was an important step forward for the company, centering our clinical and regulatory strategy while strengthening ourselves from a financial perspective,” said Kelly Martin, CEO of Radius Health. Martin commented further that “in the near-term, our focus will include completing our Phase 3 pivotal trial enrollments while adjusting our...

WALTHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect.Sean has several decades of experience in the industry across pharmaceuticals, diagnostics, and global markets. Sean worked at Abbott Laboratories for 30-years where he led the corporate business development and mergers and acquisition activity.Owen Hughes, Chairman of the Board of Radius Health, commented that, “Sean is a person of great integrity, has operated at the highest levels within the industry, and will be a terrific addition to the Board. We all look forward to his counsel and contributions as we look to progress the Radius business model.”Sean is currently on the boards of Poseida Therapeutics, a publicly traded cell...

ATLANTA, Aug. 10, 2020 (GLOBE NEWSWIRE) — Select Interior Concepts, Inc. (“SIC” or the “Company”) (NASDAQ: SIC), a premier installer and nationwide distributor of interior building products, today announced that in connection with the appointment of Deme Christian as Chief Human Resources Officer of the Company, effective immediately, the Company granted to Ms. Christian 62,500 time-based restricted stock units and 62,500 performance-based restricted stock units, each representing the right to earn one share of the Company’s common stock.  The time-based restricted stock units vest in equal annual installments over four years, subject to Ms. Christian’s continued employment with the Company.  The performance-based restricted stock units vest based on the closing price of the Company’s common stock exceeding specific price hurdles...